​

Revance Therapeutics (RVNC) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChart

Revance Therapeutics Revenue Highlights

Latest Revenue (Y)

$234.04M

Latest Revenue (Q)

$58.83M

Main Segment (Y)

Development Services

Revance Therapeutics Revenue by Period

Revance Therapeutics Revenue by Year

DateRevenueChange
2023-12-31$234.04M76.55%
2022-12-31$132.56M70.40%
2021-12-31$77.80M407.65%
2020-12-31$15.32M3610.65%
2019-12-31$413.00K-88.92%
2018-12-31$3.73M1323.28%
2017-12-31$262.00K-12.67%
2016-12-31$300.00K-
2015-12-31$300.00K-21.67%
2014-12-31$383.00K-37.93%
2013-12-31$617.00K-13.95%
2012-12-31$717.00K28.73%
2011-12-31$557.00K-

Revance Therapeutics generated $234.04M in revenue during NA 2023, up 76.55% compared to the previous quarter, and up 6276.21% compared to the same period a year ago.

Revance Therapeutics Revenue by Quarter

DateRevenueChange
2024-09-30$58.83M-10.04%
2024-06-30$65.39M25.90%
2024-03-31$51.94M-25.59%
2023-12-31$69.80M22.94%
2023-09-30$56.78M-2.34%
2023-06-30$58.13M17.84%
2023-03-31$49.33M-1.18%
2022-12-31$49.92M72.05%
2022-09-30$29.02M2.28%
2022-06-30$28.37M12.30%
2022-03-31$25.26M-2.66%
2021-12-31$25.95M31.43%
2021-09-30$19.75M5.00%
2021-06-30$18.80M41.39%
2021-03-31$13.30M19.46%
2020-12-31$11.13M190.30%
2020-09-30$3.83M1182.61%
2020-06-30$299.00K415.52%
2020-03-31$58.00K-34.83%
2019-12-31$89.00K93.48%
2019-09-30$46.00K100.00%
2019-06-30--100.00%
2019-03-31$278.00K-42.92%
2018-12-31$487.00K-79.38%
2018-09-30$2.36M244.31%
2018-06-30$686.00K255.44%
2018-03-31$193.00K421.62%
2017-12-31$37.00K-50.67%
2017-09-30$75.00K-
2017-06-30$75.00K-
2017-03-31$75.00K-
2016-12-31$75.00K-
2016-09-30$75.00K-
2016-06-30$75.00K-
2016-03-31$75.00K-
2015-12-31$75.00K-
2015-09-30$75.00K-
2015-06-30$75.00K-
2015-03-31$75.00K-
2014-12-31$75.00K-
2014-09-30$75.00K-
2014-06-30$75.00K-52.53%
2014-03-31$158.00K-48.87%
2013-12-31$309.00K95.57%
2013-09-30$158.00K110.67%
2013-06-30$75.00K-
2013-03-31$75.00K-35.90%
2012-12-31$117.00K-

Revance Therapeutics generated $58.83M in revenue during Q3 2024, up -10.04% compared to the previous quarter, and up 101.19% compared to the same period a year ago.

Revance Therapeutics Revenue Breakdown

Revance Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 22Dec 21Dec 20Dec 19Dec 18
Development Services$7.10M$5.70M$2.00M$400.00K$3.70M

Revance Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 22: Development Services (100.00%).

Quarterly Revenue by Product

Product/ServiceSep 24Jun 24Mar 24Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Sep 19Mar 19
Product$58.83M$65.33M$51.72M$54.11M$100.00K---------------
Collaboration Revenue$1.05M$100.00K$217.00K$3.00K----------------
Service---$2.66M----------------
Development Services----$100.00K$100.00K$900.00K$1.00M$1.70M$3.60M$1.70M$1.10M$1.40M$1.50M$900.00K$800.00K$300.00K$100.00K$100.00K$300.00K

Revance Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Product (98.24%), and Collaboration Revenue (1.76%).

Revance Therapeutics Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
CTEVClaritev$930.62M$241.57M
RVNCRevance Therapeutics$234.04M$58.83M
YMABY-mAbs Therapeutics$87.69M$20.90M
ITOSiTeos Therapeutics$35.00M-
CLYMClimb Bio--
VIGLVigil Neuroscience--
CKPTCheckpoint Therapeutics--

RVNC Revenue FAQ

What is Revance Therapeutics’s yearly revenue?

Revance Therapeutics's yearly revenue for 2023 was $234.04M, representing an increase of 76.55% compared to 2022. The company's yearly revenue for 2022 was $132.56M, representing an increase of 70.40% compared to 2021. RVNC's yearly revenue for 2021 was $77.8M, representing an increase of 407.65% compared to 2020.

What is Revance Therapeutics’s quarterly revenue?

Revance Therapeutics's quarterly revenue for Q3 2024 was $58.83M, a -10.04% decrease from the previous quarter (Q2 2024), and a 3.61% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $65.39M, a 25.90% increase from the previous quarter (Q1 2024), and a 12.48% increase year-over-year (Q2 2023). RVNC's quarterly revenue for Q1 2024 was $51.94M, a -25.59% decrease from the previous quarter (Q4 2023), and a 5.28% increase year-over-year (Q1 2023).

What is Revance Therapeutics’s revenue growth rate?

Revance Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 200.83%, and for the last 5 years (2019-2023) was 56568.28%.

What are Revance Therapeutics’s revenue streams?

Revance Therapeutics's revenue streams in c 22 are Development Services

What is Revance Therapeutics’s main source of revenue?

For the fiscal year ending Dec 22, the largest source of revenue of Revance Therapeutics was Development Services. This segment made a revenue of $7.1M, representing 100.00% of the company's total revenue.